Novel treatment avenue for resistant cancers: Removing SORLA protein from drug-resistant HER2-positive cancer cell lines
Study reveals wide health disparity between different ethinc groups in England
29 January 2021Cervical cancer screening rates dropped during stay-at-home order
29 January 2021Novel treatment avenue for resistant cancers: Removing SORLA protein from drug-resistant HER2-positive cancer cell lines
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska’s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitized anti-HER2 resistant breast cancer brain metastasis to targeted therapy.
